Liraglutide CAS:204656-20-2

Liraglutide is primarily used for the treatment of type 2 diabetes and obesity. For diabetes management, it is often prescribed when other oral medications have not provided adequate control of blood sugar levels. When used for diabetes, liraglutide can be taken alone or in combination with other antidiabetic medications such as metformin or sulfonylureas. In the treatment of obesity, liraglutide is used as part of a comprehensive weight management program that includes a reduced-calorie diet and increased physical activity. It is indicated for use in adults with a body mass index (BMI) of 30 kg/m² or greater, or in adults with a BMI of 27 kg/m² or greater who also have at least one weight-related condition, such as hypertension, type 2 diabetes, or dyslipidemia. Liraglutide comes in pre-filled injection pens that are self-administered subcutaneously once daily. The recommended starting dose for both diabetes and obesity treatment is 0.6 mg per day, with gradual dose escalation over several days to minimize gastrointestinal side effects. The maintenance dose for diabetes is usually 1.2 mg or 1.8 mg daily, while for obesity treatment, the maintenance dose is 3.0 mg daily. Patients using liraglutide for diabetes should continue to monitor their blood sugar levels regularly, and adjustments to other antidiabetic medications may be necessary under the guidance of a healthcare professional. For those using liraglutide for obesity, regular monitoring of weight and overall progress in the weight management program is essential. It's important to note that liraglutide may cause side effects such as nausea, vomiting, diarrhea, and constipation, particularly during the initial titration period. Patients should be advised on how to manage these side effects and should seek medical attention if they persist or worsen. Overall, the use of liraglutide can be an effective option for managing type 2 diabetes and obesity when used as directed and in conjunction with lifestyle modifications.